CS
KZR

Candriam SCA’s Kezar Life Sciences KZR Stock Holding History

Candriam SCA’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-58,496
Closed -$2.93M – 920
2021
Q1 		$2.93M Hold
58,496
– – 0.02% 459
2020
Q4 		$3.05M Sell
58,496
-1,504
-3% -$83.7K 0.02% 470
2020
Q3 		$2.9M Hold
60,000
– – 0.03% 444
2020
Q2 		$3.11M Buy
+60,000
New +$3.03M 0.03% 416

Other funds holding KZR

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Candriam SCA's KZR Position: Q2 2021 in Review

Candriam SCA sold out of Kezar Life Sciences (KZR) in Q2 2021, closing a stake of 58,496 shares — an estimated $2.93M sold.

Candriam SCA first reported a position in KZR in Q2 2020 and held it in 4 quarters. The position peaked at $3.11M in Q2 2020. 75 funds tracked by Wall St. Rank hold KZR as of Q2 2021.

  • Candriam SCA reported no remaining Kezar Life Sciences position as of Q2 2021 after selling out during the quarter.
  • Candriam SCA sold 58,496 Kezar Life Sciences shares in Q2 2021, an estimated $2.93M.
  • Candriam SCA first reported a position in Kezar Life Sciences in Q2 2020 and held it in 4 quarters.
  • Candriam SCA's Kezar Life Sciences position peaked at $3.11M in Q2 2020.
  • 75 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2021.

Based on Candriam SCA's 13F filing for Q2 2021, filed 20 Jul 2021.